MT2003-23:NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RI

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这项研究正在进行，以评估输注自然杀伤（NK）细胞的影响，给予患者接受降低强度的移植前方案和干细胞trnsplant从一个单倍体相关的捐助者。 我们的假设是，将NK细胞添加到该标准方案中将降低GVHD的发生率，而不影响植入或导致额外的+100天死亡率。 此外，NK细胞输注可能会限制移植后癌症复发的风险。 我们还在测试NK细胞输注的安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the effects of an infusion of natural killer (NK) cells given to patients receiving a reduced intensity pre-transplant regimen and stem cell trnsplant from a haploidentical related donor. Our hypothesis is that the addition of NK cells to this standard regimen will reduce the incidence of GVHD without compromising engraftment or leading to excess day +100 mortality. Additionally, the NK cell infusion may limit the risks of cancer relapse after transplant. We are also testing the safety of the NK cell infusion.